Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure

European Journal of Clinical Investigation

Volumn 38, Issue 5, 2008, Pages 296-305

  Muller Krebs S ^a   Kihm, L P ^a   Zeier, B ^a   Gross, M L ^a   Deppisch, R ^b,c   Wieslander, A ^b,c   Henle, T ^d   Penndorf, I ^d   Oh, J ^e,g   Reiser, J ^f   Nawroth, P P ^a   Zeier, M ^a   Schwenger, V ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Gambro Research   (Germany)

^c Gambro Research ^*

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Advanced glycation end products; Carbonyl compounds; Glucose degradation products; Peritoneal dialysis; Peritoneal dialysis fluids; Systemic toxicity

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ALBUMIN; CASPASE 3; GLUCOSE DEGRADATION PRODUCT; METHYLGLYOXAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLOMERULOSCLEROSIS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; MALE; NEPHRECTOMY; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; DIALYSIS SOLUTIONS; DISEASE MODELS, ANIMAL; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY FAILURE; MALE; PERITONEAL DIALYSIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 41749118714     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01945.x     Document Type: Article

References (34)

1. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001 12 : 2158 62.
2. Rocco M, Soucie JM, Pastan S, McClellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000 58 : 446 57.
3. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004 66 : 408 18.
4. Haag-Weber M, Haug U, Wieslander A, Nabut J, Deppisch R. Diurest Study Group: Decline of residual renal function in peritoneal dialysis patients depends on uptake of carbonyl compounds from the peritoneal cavity: First data of a prospective clinical trial. J Am Soc Nephrol 2003 14 : 476 A.
5. Wieslander AP, Deppisch R, Svensson E, Forsback G, Speidel R, Rippe B. In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int 1995 15 : 158 64.
6. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997 51 : 182 6.
7. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006 17 : 199 207.
8. Witowski J, Bender TO, Wisniewska-Elnur J, Ksiazek K, Passlick-Deetjen J, Breborowicz A et al. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se. Perit Dial Int 2003 23 : 381 90.
9. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003 63 : 298 305.
10. Tornig J, Amann K, Ritz E, Nichols C, Zeier M, Mall G. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996 7 : 667 75.
11. Amann K, Irzyniec T, Mall G, Ritz E. The effect of enalapril on glomerular growth and glomerular lesions after subtotal nephrectomy in the rat: a stereological analysis. J Hypertens 1993 11 : 969 75.
12. Magnotti RA Jr., Stephens GW, Rogers RK, Pesce AJ. Microplate measurement of urinary albumin and creatinine. Clin Chem 1989 35 : 1371 5.
13. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996 49 : 1304 13.
14. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999 14 : 1968 75.
15. el Nahas AM, Bassett AH, Cope GH, Le Carpentier JE. Role of growth hormone in the development of experimental renal scarring. Kidney Int 1991 40 : 29 34.
16. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 1984 26 : 137 43.
17. Kaneto H, Morrissey J, McCracken R, Reyes A, Klahr S. Enalapril reduces collagen type IV synthesis and expansion of the interstitium in the obstructed rat kidney. Kidney Int 1994 45 : 1637 47.
18. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995 47 : 1285 94.
19. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, Mall G et al. Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 1996 11 : 1003 11.
20. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998 53 : 1696 705.
21. Beller CJ, Radovits T, Seres L, Kosse J, Krempien R, Gross ML et al. Poly (ADP-ribose) polymerase inhibition reverses vascular dysfunction after gamma-irradiation. Int J Radiat Oncol Biol Phys 2006 65 : 1528 35.
22. Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK et al. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999 33 : 212 8.
23. Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007 22 : 1136 43.
24. Kriz W, Lemley KV. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 1999 8 : 489 97.
25. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003 162 : 1123 37.
26. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003 14 : 1383 95.
27. Krause R, Kuhn J, Penndorf I, Knoll K, Henle T. N-Terminal pyrazinones: a new class of peptide-bound advanced glycation end-products. Amino Acids 2004 27 : 9 18.
28. Catalan MP, Santamaria B, Reyero A, Ortiz A, Egido J. 3,4-di-deoxyglucosone-3-ene promotes leukocyte apoptosis. Kidney Int 2005 68 : 1303 11.
29. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005 54 : 2424 9.
30. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002 277 : 20309 15.
31. Wang Y, Beck W, Deppisch R, Marshall SM, Hoenich NA, Thompson MG. Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors. Am J Physiol Cell Physiol 2007 293 : C328 36.
32. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 1994 91 : 9436 40.
33. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005 25 : 248 55.
34. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006 21 : 2893 9.